Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis

American Journal of Hematology

Volumn 85, Issue 8, 2010, Pages 627-629

  Adams, Betsy ^a   Lazarchick, John ^a   Medina, Ana Maria ^a   Willner, Ira R ^a   Neville, Brad ^a   Murphy, Edward ^a   Stuart, Robert ^a   Costa, Luciano J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CASE REPORT; CLASSICAL HODGKIN LYMPHOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; FEVER; GINGIVA; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; LYMPHOPROLIFERATIVE DISEASE; NIGHT SWEAT; POLYMYOSITIS; PRIORITY JOURNAL; RARE DISEASE; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; ULCER; WEIGHT REDUCTION; DIFFERENTIAL DIAGNOSIS; DRUG COMBINATION; EPSTEIN BARR VIRUS INFECTION; GINGIVA DISEASE; HODGKIN DISEASE; IATROGENIC DISEASE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; JAW DISEASE; LETTER; MOUTH ULCER; PHYSIOLOGY; REMISSION; VIROLOGY; VIRUS ACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GINGIVAL DISEASES; HEPATITIS, AUTOIMMUNE; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IATROGENIC DISEASE; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS; MANDIBULAR DISEASES; MYCOPHENOLIC ACID; ORAL ULCER; PREDNISONE; REMISSION INDUCTION; VIRUS ACTIVATION;

EID: 77955482973     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21753     Document Type: Article

References (19)

1. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 1999;12:200-17.
2. Biemer JJ. Malignant lymphomas associated with immunodeficiency states. Ann Clin Lab Sci 1990;20:175-191.
3. Gaulard PSS, Harris NL, Jaffe ES, et al. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon:International Agency for Research on Cancer; 2008. p 350.
4. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-1321.
5. Ellman MH, Hurwitz H, Thomas C, et al. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 1991;18:1741-1743.
6. Kingsmore SF, Hall BD, Allen NB, et al. Association of methotrexate, rheumatoid arthritis and lymphoma: Report of 2 cases and literature review. J Rheumatol 1992;19:1462-1465.
7. Shiroky JB, Frost A, Skelton JD, et al. Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol 1991;18:1172-1175.
8. Ferraccioli GF, Casatta L, Bartoli E, et al. Epstein-Barr virus-associated Hodgkin's lymphoma in a rheumatoid arthritis patient treated with methotrexate and cyclosporin A. Arthritis Rheum 1995;38:867-868.
9. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14: 1943-1949.
10. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-267.
11. Kamel OW, Weiss LM, van de Rijn M, et al. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol 1996;20:1279-1287.
12. Kamel OW, van de Rijn M, LeBrun DP, et al. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 1994;25: 638-643.
13. Koch DG, Christiansen L, Lazarchick J, et al. Posttransplantation lymphoproliferative disorder-the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl 2007; 13:904-912.
14. Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev 2007;7:96-101.
15. Kamel OW: Iatrogenic lymphoproliferative disorders in nontransplantation settings. Semin Diagn Pathol 1997;14:27-34.
16. Tsang HH, Trendell-Smith NJ, Wu AK, et al. Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus. Lupus, 2009
17. Nalesnik MA, Randhawa P, Demetris AJ, et al. Lymphoma resembling Hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipient. Cancer 1993;72:2568-2573.
18. Blaes AH, Cao Q, Wagner JE, et al. Monitoring and preemptive rituximab therapy for epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant 16:287-291
19. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era. J Clin Oncol 28:1038-1046.